Patents by Inventor Nicholas J Laping

Nicholas J Laping has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of Treatment
    Publication number: 20090281110
    Abstract: This invention relates to the use of sulfonamide substituted diphenyl urea compounds to treat endometriosis.
    Type: Application
    Filed: June 22, 2007
    Publication date: November 12, 2009
    Inventors: Jakob Busch-Petersen, Jeffery D. Bray, Nicholas J. Laping, Eugene T. Grygielko, Richard M. Goodman
  • Human MAD proteins and uses thereof
    Publication number: 20020025558
    Abstract: Human MADr3 or MADr4 polypeptides and DNA (RNA) encoding such MADr3 or MADr4 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such MADr3 or MADr4, or compounds which inhibit or stimulate MADr3 or MADr4 for stimulating wound healing, and treating cancers, among others, are also disclosed. Agonist and antagonists of these MAD proteins and methods of their use are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the MADr3 or MADr4 and for detecting altered levels of the polypeptide in a host.
    Type: Application
    Filed: August 15, 2001
    Publication date: February 28, 2002
    Inventor: Nicholas J. Laping
  • Human MAD proteins and uses thereof
    Patent number: 6309856
    Abstract: Human MADr3 or MADr4 polypeptides and DNA (RNA) encoding such MADr3 or MADr4 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such MADr3 or MADr4, or compounds which inhibit or stimulate MADr3 or MADr4 for stimulating wound healing, and treating cancers, among others, are also disclosed. Agonist and antagonists of these MAD proteins and methods of their use are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the MADr3 or MADr4 and for detecting altered levels of the polypeptide in a host.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: October 30, 2001
    Assignee: SmithKline Beecham Corporation
    Inventor: Nicholas J. Laping
  • CRFG-1b, a target and marker for chronic renal failure
    Patent number: 6255471
    Abstract: CRFG-1b polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CRFG-1b polypeptides and polynucleotides in the design of protocols for the treatment of chronic renal disease, renal ischemia, diabetic nephropathy, acute renal failure, neurodegenerative disease, and Alzheimer's disease, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: July 3, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Nicholas J Laping, Barbara Olson, Yuan Zhu
  • CRFG-1a, a target and marker for chronic renal failure
    Patent number: 6127522
    Abstract: CRFG-1a polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CRFG-1a polypeptides and polynucleotides in the design of protocols for the treatment of chronic renal disease, renal ischemia, diabetic nephropathy, acute renal failure, Neurodegenerative disease, and Alzeimer's disease, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: November 16, 1998
    Date of Patent: October 3, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Nicholas J Laping, Barbara Olson, Yuan Zhu
  • CRFG-1a, a target and marker for chronic renal failure
    Patent number: 5879908
    Abstract: CRFG-1a polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CRFG-1a polypeptides and polynucleotides in the design of protocols for the treatment of chronic renal disease, renal ischemia, diabetic nephropathy, acute renal failure, Neurodegenerative disease, and Alzheimer's disease, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: March 9, 1999
    Assignee: Smithkline Beecham Corporation
    Inventors: Nicholas J Laping, Barbara Olson, Yuan Zhu
  • DNA encoding human MAD proteins
    Patent number: 5866693
    Abstract: Human MADr3 or MADr4 polypeptides and DNA (RNA) encoding such MADr3 or MADr4 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such MADr3 or MADr4, or compounds which inhibit or stimulate MADr3 or MADr4 for stimulating wound healing, and treating cancers, among others, are also disclosed. Agonist and antagonists of these MAD proteins and methods of their use are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the MADr3 or MADr4 and for detecting altered levels of the polypeptide in a host.
    Type: Grant
    Filed: October 16, 1996
    Date of Patent: February 2, 1999
    Assignee: SmithKline Beecham Corporation
    Inventor: Nicholas J. Laping